JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - TWIST BIOSCIENCE CORP
Explicit Guidance:
- FY2027 revenue guidance of $550–$560 million, reflecting low 20% year-over-year growth.
- AI Discovery revenue guidance of at least $100 million in FY2027, up from $59 million in FY2026 (a 75%+ actual growth; triple-digit growth was seen in FY2026).
- Capital expenditures (CapEx) of $75 million in FY2027 and $75 million in FY2028, totaling $150 million over the next two years.
Business-Segment Outlook:
- Total Serviceable Addressable Market (TAM): Expanded to $7 billion in 2026, with a line of sight to $13 billion driven by expansion into new DNA "flavors."
- AI-Enabled Drug Discovery: Anticipated to be a primary upside driver beyond the $100M guide, limited primarily by current capacity constraints. The business model is shifting from "lumpy" pilot orders to recurring, predictable "run-rate" revenue as customers progress to Phase 3 (production/discovery optimization).
- NGS & MRD: MRD (Minimal Residual Disease) is expected to be a "huge driver" of growth in FY2027 and beyond. Demand is shifting toward high-sensitivity MRD requiring thousands of probes, leveraging Twist's unique supply advantage.
- Academic/Government: Expecting potential upside if funding environments rebound; currently gaining meaningful market share even in a tough market due to value proposition (quality, speed, pricing).
- Cell-Free Synthesis: Recently launched to the entire market; unique competitive advantage as the only scaled supplier for both single-domain and multi-domain proteins, offering a 2-week faster turnaround than cell-based methods.
- Pooled Discovery: Strategic initiative to shift the market from arrayed discovery to "pooled discovery" to significantly reduce price-per-data-point and increase differentiation.
Market and Competitive Outlook:
- Customer Cohorts: AI adoption is expanding beyond the "Magnificent 7" tech-native firms into traditional pharma (e.g., Eli Lilly's "Tune Lab"), with significant growth opportunity among pharma not yet converted to AI workflows.
- Modality Evolution: Increasing demand expected as customers graduate from simple single-domain proteins (e.g., VHH) to complex multi-domain antibodies (IgG) and multi-specific IgGs, requiring significantly higher data points.
- Competitive Positioning: Twist differentiates via the ability to scale pooled DNA synthesis at high quality and speed, a capability competitors cannot match at scale.
- Market Dynamics: In a challenging economy, customers are more likely to switch suppliers for better value, facilitating Twist's share gains.
Macro / Industry Outlook:
- Economic Environment: Management views the company's value proposition (high quality/speed/price) as "stronger in a tough market" as customers seek cost efficiency.
- Regulatory/Clinical Trends: Anticipated shift in NGS/MRD standards toward "high-sensitivity" testing, which acts as a volume driver due to the requirement for hundreds to thousands of probes per test.
Strategic Initiatives:
- Capacity Expansion: Adding capacity to support AI drug discovery acceleration, including increasing "riders" from 10 to 16 over the coming year and expanding automation in "Gene Lab 2" and protein characterization equipment.
- New Product Launches: Full global launch of cell-free synthesis capabilities (previously in early access); expansion of pooled discovery offerings to lower data costs.
- Infrastructure: Significant CapEx investment phased over 2027–2028 to prevent bottlenecks in high-growth AI segments, specifically targeting synthesis, lab automation, and characterization.
- Technical Execution: Strategy relies on "copy-pasting" existing operating instruments and managing software integration, minimizing technical risk despite multi-fold capacity scaling.
Risks and Headwinds to Outlook:
- Capacity Constraints: Current ability to realize revenue beyond the $100M AI guide is limited by the time required to onboard new capacity (specifically long lead times on "riders").
- Software Integration: Identified as the "rate-limiting step" in scaling new capacity; execution risk exists in integrating software to support larger menus and higher throughput.
- Revenue Volatility in Early Phases: AI discovery revenue can be "lumpy" during Phase 2 (model building) before stabilizing in Phase 3 (production).
- Unpriced Upside: Guidance does not fully account for potential upside from a broader academic/government funding recovery or accelerated share gains if market conditions improve.
Management Tone on the Future:
- Confidence Level: High confidence in the "march to deliver" and the ability to hit EBITDA break-even. Management expresses "sense of urgency" and excitement regarding AI adoption.
- Guidance Philosophy: Conservative; guidance is based on demand with a "high degree of confidence." Upside is expected but not included in the formal guidance due to capacity timing.
- Strategic Confidence: Repeated emphasis on the "compounding plan" of the AI customer lifecycle and the "low technical risk" of scaling via existing validated processes.
Miscellaneous:
- EBITDA: Achieved break-even EBITDA for the first time in the most recent quarter, marking a milestone toward "best-in-class" financial performance compared to peers.
- Timeline: 2025 revenue was $21 million; 2026 revenue was $59 million (175% growth); 2027 AI guide is $100 million minimum.
- Company
- TWIST BIOSCIENCE CORP
- Keywords
- TWIST BIOSCIENCE CORP